About Medicaps Limited
Data last updated:
Medicaps Limited is a public limited company based in Indore, Madhya Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 06 August 1983 and has been in existence for over 43 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN L70100MP1983PLC002231. Its GSTIN is 23AABCM1905G1Z1 (Madhya Pradesh). It is a listed company as per MCA records. Its shares are listed on BSE: 523144 and NSE: MEDICAPQ.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.47 Cr. It was formerly known as Medicaps Pvt Limited. It is led by directors including Alok K Garg (Managing Director) and Ramesh Chandra Mittal.
Its last annual general meeting (AGM) was held on 18 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Indore, Madhya Pradesh.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹12.45 Cr, a decline of 51.1% compared to the previous year. For the same year it recorded a net loss of ₹10.73 Cr (net margin -86.2%) and EBITDA of -₹9.4 Cr (EBITDA margin -75.5%). The net worth stands at ₹111.61 Cr (down 8% YoY). Total assets are valued at ₹112.35 Cr (down 7.8% YoY).
The company has about 2 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Medi-Caps. As per MCA filings, the company has open charges of ₹20 Lakh and satisfied charges of ₹2.22 Cr on record. Court records list 22 cases involving the company, including 16 filed by the company and 6 filed against it; 10 cases are pending. The company has 23 deals on record (23 market trades); the latest was in January 2025.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medicaps.com.
Company details
CIN history
Medicaps has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L70100MP1983PLC002231, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L70100MP1983PLC002231 | Current |
| U24232MP1983PLC002231 | Previous |
| L24232MP1983PLC002231 | Previous |
Contact details
Medicaps Limited's registered office is in Indore, Madhya Pradesh. Its website is medicaps.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address201 Pushpratna Paradise, 9/5 New Palasiya, Indore, Madhya Pradesh, India – 452001
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Medicaps Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Medicaps operates one associated brand: Medi-Caps. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of empty gelatin capsules | medicaps.com |
Business activity
The main business activity of Medicaps is real estate. In detail, this covers real estate activities with own or leased property.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| L | Real Estate | L1 | Real estate activities with own or leased property |
To see the full business activity and turnover split of Medicaps Limited, buy the company report.
Financials of Medicaps Limited
FY 2025-26 filings availableMedicaps Limited reported revenue of ₹12.45 Cr (down 51.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 12.45 | 25.48 | 27.35 | 49.37 | 69.87 | 57.42 | 43.05 |
| Revenue growth | -51.1% | -6.8% | -44.6% | -29.3% | +21.7% | +33.4% | - |
| EBITDA | (9.40) | (1.81) | 0.01 | 5.08 | 10.07 | 10.86 | (6.77) |
| EBITDA margin | -75.5% | -7.1% | +0.0% | +10.3% | +14.4% | +18.9% | -15.7% |
| Profit before tax | (3.02) | (0.85) | (1.24) | 4.81 | 10.10 | 11.13 | (5.85) |
| Net profit | (10.73) | (2.36) | (2.43) | 1.22 | 9.62 | 11.26 | (6.28) |
| Net profit margin | -86.2% | -9.3% | -8.9% | +2.5% | +13.8% | +19.6% | -14.6% |
| EPS (₹) | (2.44) | (0.46) | (1.80) | 1.41 | 8.08 | 8.92 | (4.69) |
| Balance sheet | |||||||
| Total assets | 112 | 122 | 122 | 119 | 117 | 105 | 91.47 |
| Net worth | 112 | 121 | 121 | 119 | 116 | 105 | 90.95 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Cash & bank | 0.50 | 0.41 | 0.32 | 1.11 | 9.75 | 6.81 | 1.25 |
| Net working capital | 20.90 | 21.64 | 24.61 | 28.22 | 26.53 | 17.11 | 11.31 |
| Cash flow | |||||||
| Cash from operations | (7.02) | 5.07 | 6.94 | (6.08) | 7.02 | 15.32 | 4.63 |
| Cash from investing | 7.11 | (4.98) | (7.73) | (2.56) | (4.08) | (9.70) | (5.80) |
| Cash from financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) | (0.06) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.79 | 3.45 | 4.30 | 2.02 | 2.69 | 6.97 | 4.02 | 8.29 |
| Revenue growth (YoY) | +3.7% | -50.5% | +7.0% | -75.6% | -56.6% | - | - | - |
| Other income | 0.05 | 5.59 | 0.76 | 1.53 | 0.33 | 2.14 | 0.16 | 0.29 |
| EBITDA | (1.83) | (2.06) | (1.06) | (2.91) | (3.37) | (0.22) | (1.78) | 0.45 |
| EBITDA margin | -67.3% | -60.2% | -24.7% | -144.8% | -125.7% | -3.2% | -44.4% | +5.4% |
| Depreciation | 0.45 | 0.50 | 0.44 | 0.44 | 0.44 | 0.44 | 0.43 | 0.43 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 |
| Profit before tax | (2.23) | 3.03 | (0.74) | (1.82) | (3.49) | 1.46 | (2.05) | 0.31 |
| Tax | 0.00 | (0.01) | 0.03 | 0.00 | 0.00 | (0.27) | 0.00 | 0.00 |
| Net profit | (2.23) | 3.04 | (0.77) | (1.82) | (3.49) | 1.73 | (2.05) | 0.31 |
| EPS (₹) | (1.79) | 2.44 | (0.61) | (1.46) | (2.80) | 1.38 | (1.64) | 0.25 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2.31 | 2.42 | 7.17 | 0.10 | 0.00 | 0.00 | 10.91 |
| Revenue growth | -4.6% | -66.3% | +7070.0% | - | - | -100.0% | - |
| EBITDA | (0.50) | (0.10) | 4.84 | (0.40) | (0.56) | (0.12) | (9.08) |
| EBITDA margin | -21.7% | -4.1% | +67.5% | -400.0% | - | - | -83.2% |
| Profit before tax | (0.11) | 0.30 | 4.83 | 0.15 | (0.02) | (0.12) | (8.33) |
| Net profit | (0.61) | 0.19 | 3.77 | (0.49) | (0.49) | 0.01 | (8.68) |
| Net profit margin | -26.4% | +7.9% | +52.6% | -490.0% | - | - | -79.6% |
| EPS (₹) | (0.11) | 0.45 | 3.12 | 0.12 | (0.03) | (0.09) | (6.68) |
| Balance sheet | |||||||
| Total assets | 66.71 | 67.34 | 66.49 | 61.11 | 61.29 | 61.10 | 60.16 |
| Net worth | 66.71 | 67.34 | 66.49 | 61.11 | 61.29 | 60.97 | 59.85 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Cash & bank | 0.01 | 0.05 | 0.05 | 0.04 | 0.79 | 0.73 | 0.75 |
| Net working capital | 8.60 | 8.65 | 9.51 | 7.06 | 5.23 | 3.84 | 4.75 |
| Cash flow | |||||||
| Cash from operations | (0.47) | 1.85 | 3.09 | (2.60) | (0.95) | 2.24 | (0.92) |
| Cash from investing | 0.42 | (1.85) | (3.09) | 1.85 | 1.01 | (2.19) | (0.40) |
| Cash from financing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) | (0.06) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.53 | 0.77 | 1.00 | 0.00 | 0.89 | 0.26 | 0.98 |
| Revenue growth (YoY) | - | -40.5% | +196.2% | +2.0% | -100.0% | - | - | - |
| Other income | 0.00 | 0.08 | 0.17 | 0.01 | 0.31 | 0.27 | 0.09 | 0.10 |
| Total expenses | 0.65 | 0.88 | 0.59 | 0.68 | 0.67 | 0.68 | 0.57 | 0.59 |
| EBITDA | (0.55) | (0.35) | 0.18 | 0.32 | (0.67) | 0.21 | (0.31) | 0.39 |
| EBITDA margin | -1375.0% | -68.6% | +23.4% | +32.0% | - | +23.9% | -124.0% | +40.6% |
| Depreciation | 0.05 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.60) | (0.34) | 0.31 | 0.29 | (0.40) | 0.44 | (0.26) | 0.45 |
| Tax | 0.00 | (0.01) | 0.03 | 0.00 | 0.00 | (0.27) | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.79 | 3.45 | 4.30 | 2.02 | 2.69 | 6.97 | 4.02 | 8.29 |
| Revenue growth (YoY) | +3.7% | -50.5% | +7.0% | -75.6% | -56.6% | - | - | - |
| Other income | 0.05 | 5.59 | 0.76 | 1.53 | 0.33 | 2.14 | 0.16 | 0.29 |
| EBITDA | (1.83) | (2.06) | (1.06) | (2.91) | (3.37) | (0.22) | (1.78) | 0.45 |
| EBITDA margin | -67.3% | -60.2% | -24.7% | -144.8% | -125.7% | -3.2% | -44.4% | +5.4% |
| Depreciation | 0.45 | 0.50 | 0.44 | 0.44 | 0.44 | 0.44 | 0.43 | 0.43 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 |
| Profit before tax | (2.23) | 3.03 | (0.74) | (1.82) | (3.49) | 1.46 | (2.05) | 0.31 |
| Tax | 0.00 | (0.01) | 0.03 | 0.00 | 0.00 | (0.27) | 0.00 | 0.00 |
| Net profit | (2.23) | 3.04 | (0.77) | (1.82) | (3.49) | 1.73 | (2.05) | 0.31 |
| EPS (₹) | (1.79) | 2.44 | (0.61) | (1.46) | (2.80) | 1.38 | (1.64) | 0.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 12.45 | 25.48 | 27.35 | 49.37 | 69.87 | 57.42 | 43.05 |
| Revenue growth | -51.1% | -6.8% | -44.6% | -29.3% | +21.7% | +33.4% | - |
| Other income | 8.21 | 2.73 | 0.48 | 1.60 | 1.95 | 1.89 | 2.87 |
| Total expenses | 21.85 | 27.29 | 27.34 | 44.29 | 59.80 | 46.56 | 49.82 |
| Employee cost | 5.97 | 5.81 | 5.21 | 5.65 | 5.62 | 4.96 | 10.70 |
| EBITDA | (9.40) | (1.81) | 0.01 | 5.08 | 10.07 | 10.86 | (6.77) |
| EBITDA margin | -75.5% | -7.1% | +0.0% | +10.3% | +14.4% | +18.9% | -15.7% |
| Depreciation | 1.81 | 1.72 | 1.69 | 1.74 | 1.81 | 1.52 | 1.83 |
| Interest | 0.02 | 0.05 | 0.04 | 0.13 | 0.11 | 0.10 | 0.12 |
| Profit before tax | (3.02) | (0.85) | (1.24) | 4.81 | 10.10 | 11.13 | (5.85) |
| Tax | 0.02 | (0.27) | 1.00 | 3.06 | 0.01 | (0.01) | 0.01 |
| Net profit | (10.73) | (2.36) | (2.43) | 1.22 | 9.62 | 11.26 | (6.28) |
| Net profit margin | -86.2% | -9.3% | -8.9% | +2.5% | +13.8% | +19.6% | -14.6% |
| EPS (₹) | (2.44) | (0.46) | (1.80) | 1.41 | 8.08 | 8.92 | (4.69) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
| Reserves & surplus | 99.14 | 109 | 109 | 106 | 104 | 92.24 | 78.48 |
| Shareholders' funds (net worth) | 112 | 121 | 121 | 119 | 116 | 105 | 90.95 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Total liabilities | 112 | 122 | 122 | 119 | 117 | 105 | 91.47 |
| Assets | |||||||
| Gross block | 93.16 | 92.45 | 92.51 | 91.09 | 92.53 | 90.28 | 88.07 |
| Net block | 56.29 | 57.18 | 58.64 | 58.91 | 59.31 | 58.12 | 57.29 |
| Capital work in progress | 0.00 | 0.08 | 0.00 | 0.00 | 0.24 | 0.54 | 0.97 |
| Investments | 34.82 | 43.04 | 38.38 | 32.07 | 30.67 | 29.41 | 21.97 |
| Inventories | 2.94 | 3.20 | 5.74 | 7.07 | 11.85 | 6.71 | 5.45 |
| Sundry debtors | 6.92 | 8.79 | 10.82 | 8.46 | 10.07 | 6.39 | 4.41 |
| Cash & bank balances | 0.50 | 0.41 | 0.32 | 1.11 | 9.75 | 6.81 | 1.25 |
| Loans & advances | 13.25 | 12.34 | 12.99 | 17.97 | 8.06 | 6.47 | 3.51 |
| Total current assets | 23.61 | 24.74 | 29.87 | 34.61 | 39.73 | 26.38 | 14.62 |
| Total current liabilities | 2.71 | 3.10 | 5.26 | 6.39 | 13.20 | 9.27 | 3.31 |
| Net working capital | 20.90 | 21.64 | 24.61 | 28.22 | 26.53 | 17.11 | 11.31 |
| Total assets | 112 | 122 | 122 | 119 | 117 | 105 | 91.47 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.41 | 0.32 | 1.11 | 9.75 | 6.81 | 1.25 | 2.48 |
| Net cash from operating activities | (7.02) | 5.07 | 6.94 | (6.08) | 7.02 | 15.32 | 4.63 |
| Net cash from investing activities | 7.11 | (4.98) | (7.73) | (2.56) | (4.08) | (9.70) | (5.80) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) | (0.06) |
| Net change in cash | 0.09 | 0.09 | (0.79) | (8.64) | 2.95 | 5.56 | (1.23) |
| Closing cash | 0.50 | 0.41 | 0.32 | 1.11 | 9.75 | 6.81 | 1.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -51.1% | -6.8% | -44.6% | -29.3% | +21.7% | +33.4% | - |
| EBITDA growth | -419.3% | - | -99.8% | -49.6% | -7.3% | +260.4% | - |
| PBT growth | -255.3% | +31.5% | - | -52.4% | -9.3% | +9998.0% | - |
| Net income growth | -354.7% | +2.9% | -299.2% | -87.3% | -14.6% | +279.3% | - |
| Revenue CAGR (3Y) | -36.8% | -28.6% | -21.9% | +4.7% | +10.5% | +2.3% | -0.8% |
| EBITDA CAGR (3Y) | - | - | -90.3% | - | +28.7% | +71.1% | - |
| Profitability & leverage | |||||||
| Net income margin | -24.4% | -2.3% | -8.2% | +3.5% | +14.4% | +19.4% | -13.6% |
| Return on capital employed | -9.1% | -2.1% | -1.2% | +3.7% | +9.2% | +11.4% | -6.1% |
| Return on net worth | -9.2% | -1.9% | -2.0% | +1.1% | +9.1% | +11.4% | -6.3% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | -0.18 | -1.42 | -2.38 | 3.89 | 1.33 | 1.07 | -1.40 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.13 | 0.28 | 0.30 | 0.54 | 0.76 | 0.64 | 0.51 |
| Inventory turnover | 4.06 | 5.70 | 4.27 | 5.22 | 7.53 | 9.44 | 5.50 |
| Debtors turnover | 1.58 | 2.60 | 2.84 | 5.33 | 8.49 | 10.63 | 5.22 |
| EPS (₹) | (2.44) | (0.46) | (1.80) | 1.41 | 8.08 | 8.92 | (4.69) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 89.50 | 97.25 | 97.02 | 95.09 | 93.23 | 83.97 | 72.94 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.10 | 0.53 | 0.77 | 1.00 | 0.00 | 0.89 | 0.26 | 0.98 |
| Revenue growth (YoY) | - | -40.5% | +196.2% | +2.0% | -100.0% | - | - | - |
| Other income | 0.00 | 0.08 | 0.17 | 0.01 | 0.31 | 0.27 | 0.09 | 0.10 |
| Total expenses | 0.65 | 0.88 | 0.59 | 0.68 | 0.67 | 0.68 | 0.57 | 0.59 |
| EBITDA | (0.55) | (0.35) | 0.18 | 0.32 | (0.67) | 0.21 | (0.31) | 0.39 |
| EBITDA margin | -1375.0% | -68.6% | +23.4% | +32.0% | - | +23.9% | -124.0% | +40.6% |
| Depreciation | 0.05 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.60) | (0.34) | 0.31 | 0.29 | (0.40) | 0.44 | (0.26) | 0.45 |
| Tax | 0.00 | (0.01) | 0.03 | 0.00 | 0.00 | (0.27) | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.31 | 2.42 | 7.17 | 0.10 | 0.00 | 0.00 | 10.91 |
| Revenue growth | -4.6% | -66.3% | +7070.0% | - | - | -100.0% | - |
| Other income | 0.58 | 0.56 | 0.15 | 0.64 | 0.64 | 0.00 | 1.12 |
| Total expenses | 2.81 | 2.52 | 2.33 | 0.50 | 0.56 | 0.12 | 19.99 |
| Employee cost | 1.01 | 0.97 | 0.50 | 0.23 | 0.45 | 0.00 | 5.55 |
| EBITDA | (0.50) | (0.10) | 4.84 | (0.40) | (0.56) | (0.12) | (9.08) |
| EBITDA margin | -21.7% | -4.1% | +67.5% | -400.0% | - | - | -83.2% |
| Depreciation | 0.19 | 0.16 | 0.16 | 0.09 | 0.09 | 0.00 | 0.36 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 |
| Profit before tax | (0.11) | 0.30 | 4.83 | 0.15 | (0.02) | (0.12) | (8.33) |
| Tax | 0.02 | (0.27) | 0.94 | 0.00 | 0.01 | (0.01) | 0.01 |
| Net profit | (0.61) | 0.19 | 3.77 | (0.49) | (0.49) | 0.01 | (8.68) |
| Net profit margin | -26.4% | +7.9% | +52.6% | -490.0% | - | - | -79.6% |
| EPS (₹) | (0.11) | 0.45 | 3.12 | 0.12 | (0.03) | (0.09) | (6.68) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
| Reserves & surplus | 54.24 | 54.87 | 54.02 | 48.64 | 48.82 | 48.50 | 47.38 |
| Shareholders' funds (net worth) | 66.71 | 67.34 | 66.49 | 61.11 | 61.29 | 60.97 | 59.85 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Total liabilities | 66.71 | 67.34 | 66.49 | 61.11 | 61.29 | 61.10 | 60.16 |
| Assets | |||||||
| Gross block | 17.82 | 17.71 | 18.03 | 16.99 | 19.99 | 21.13 | 21.65 |
| Net block | 3.31 | 3.18 | 3.34 | 2.46 | 2.77 | 3.25 | 3.63 |
| Capital work in progress | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 55.13 | 55.81 | 54.03 | 51.98 | 53.68 | 54.39 | 52.15 |
| Inventories | 0.02 | 0.03 | 0.03 | 0.00 | 0.00 | 0.05 | 0.53 |
| Sundry debtors | 2.95 | 3.66 | 4.65 | 2.24 | 2.24 | 2.41 | 2.66 |
| Cash & bank balances | 0.01 | 0.05 | 0.05 | 0.04 | 0.79 | 0.73 | 0.75 |
| Loans & advances | 5.85 | 5.18 | 5.95 | 4.86 | 2.28 | 1.75 | 1.78 |
| Total current assets | 8.83 | 8.92 | 10.68 | 7.14 | 5.31 | 4.94 | 5.72 |
| Total current liabilities | 0.23 | 0.27 | 1.17 | 0.08 | 0.08 | 1.10 | 0.97 |
| Net working capital | 8.60 | 8.65 | 9.51 | 7.06 | 5.23 | 3.84 | 4.75 |
| Total assets | 66.71 | 67.34 | 66.49 | 61.11 | 61.29 | 61.10 | 60.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.05 | 0.05 | 0.04 | 0.79 | 0.73 | 0.75 | 2.13 |
| Net cash from operating activities | (0.47) | 1.85 | 3.09 | (2.60) | (0.95) | 2.24 | (0.92) |
| Net cash from investing activities | 0.42 | (1.85) | (3.09) | 1.85 | 1.01 | (2.19) | (0.40) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.06) | (0.06) |
| Net change in cash | (0.05) | 0.01 | 0.00 | (0.75) | 0.06 | (0.02) | (1.38) |
| Closing cash | 0.01 | 0.05 | 0.05 | 0.04 | 0.79 | 0.73 | 0.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -4.6% | -66.3% | +7070.0% | - | - | -100.0% | - |
| EBITDA growth | -400.0% | -102.1% | +1310.0% | +28.6% | -366.7% | +98.7% | - |
| PBT growth | - | -93.8% | +3120.0% | +9998.0% | +83.3% | +98.6% | - |
| Net income growth | -421.1% | -95.0% | +869.4% | 0.0% | -5000.0% | +100.1% | - |
| Revenue CAGR (3Y) | +184.8% | - | - | -79.1% | -100.0% | -100.0% | -21.7% |
| EBITDA CAGR (3Y) | +7.7% | -43.7% | - | -64.7% | +141.0% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -5.6% | +23.6% | +54.3% | +150.0% | - | - | -76.4% |
| Return on capital employed | -0.9% | -0.1% | +7.6% | -0.6% | -0.9% | 0.0% | -12.9% |
| Return on net worth | -0.9% | +0.3% | +6.1% | -0.8% | -0.8% | +0.0% | -13.1% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | -1.54 | 0.00 | -0.11 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.13 | 0.14 | 0.41 | 0.01 | 0.00 | 0.00 | 0.58 |
| Inventory turnover | 92.40 | 80.67 | 478.00 | 0.00 | 0.00 | 0.00 | 3.45 |
| Debtors turnover | 0.70 | 0.58 | 2.08 | 0.04 | 0.00 | 0.00 | 2.90 |
| EPS (₹) | (0.11) | 0.45 | 3.12 | 0.12 | (0.03) | (0.09) | (6.68) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 53.50 | 54.00 | 53.32 | 49.00 | 49.15 | 48.89 | 47.99 |
To see the full year-wise statements and ratios of Medicaps Limited, buy the company report.
Board of directors of Medicaps Limited
Medicaps has 6 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Alok K Garg Also directs: Medgel Private Limited | Managing Director | 01 Apr 2007 | 19 Years 7 Months | Current |
| Ramesh Chandra Mittal | Director | 06 Aug 1983 | 43 Years 2 Months | Current |
| Ashok Agrawal Omprakash Also directs: Medgel Private Limited | Director | 25 Jul 2017 | 9 Years 3 Months | Current |
| Kusum Mittal | Director | 04 May 1991 | 35 Years 5 Months | Current |
| Dharmendra Solanki | Director | 05 Feb 2021 | 5 Years 8 Months | Current |
| Gajendra Singh | Director | 11 Aug 2023 | 3 Years 2 Months | Current |
Auditor
Medicaps Limited is audited by Rawka & Associate for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Rawka & Associate | FY 2023 | 021606C |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 51.40%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 48.60%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 51.40% | 51.40% | 50.80% | 50.80% |
| Public | 48.60% | 48.60% | 49.20% | 49.20% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 24 Mar 1992 | 90207250 | Bank of Baroda | ₹3 Lakh | Open | |
| 05 Oct 1990 | 90202622 | Bank of Baroda | ₹10 Lakh | Open | |
| 24 Jul 1986 | 90204557 | Bank of Baroda | ₹7 Lakh | Open | |
| 03 Mar 2018 | 100193845 | Axis Bank Limited | ₹17.46 Lakh | Satisfied | |
| 22 Jan 1996 | 90207759 | I.D.B.I. Bank Ltd. | ₹1.15 Cr | Satisfied |
To see the full charge records of Medicaps Limited, buy the company report.
Total charge records: 6 View all charges
Deals & funding
Medicaps Limited has 23 deals on record (23 market trades); the latest was in January 2025.
Deals on record (5 of 23)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2025 | Market trade | ₹71.8 Lakh | Buyer: an individual |
| Apr 2024 | Market trade | ₹43.7 Lakh | Buyer: an individual Seller: an individual |
| Mar 2023 | Market trade | ₹47.9 Lakh | Buyer: an individual Seller: an individual |
| Jun 2021 | Market trade | ₹42.7 Lakh | Seller: an individual |
| Dec 2015 | Market trade | ₹53.8 Lakh | Buyer: Yuga Stocks & Commodities Private Limited Seller: Yuga Stocks & Commodities Private Limited |
To see the full deal history of Medicaps Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Medicaps Limited has 22 court cases on record: 16 filed by Medicaps, 6 filed against it. 10 cases are pending and 12 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 21 | 5 | 10 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 22)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Indore, Madhya Pradesh | Court case (SC NIA) | Filed by the company against M/S Beloorbayir Biotech Ltd. and 1 other | Pending |
| District court, Indore, Madhya Pradesh | Court case (UN CR) | Filed by the company against M/S Beloorbayir Biotech Ltd. and 3 others | Pending |
| District court, Indore, Madhya Pradesh | Court case (RCS B) | Filed against the company by Indusind Bank Ltd | Disposed |
| District court, Dhar, Madhya Pradesh | Court case (RCS A) | Filed by the company against individuals | Pending |
| District court, Indore, Madhya Pradesh | Court case (SC NIA) | Filed by the company against M/S Shreechem Pharmaceuticls Pvt. Ltd. Through Directors and 1 other | Pending |
To see the full case history of Medicaps Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Medicaps Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Medicaps has 1 subsidiary company. This group structure data is as of FY 2022. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Medgel Private Limited | U24239MP2007PTC019204 |
To see the full group structure of Medicaps Limited, buy the company report.
Employees & EPFO
Medicaps Limited has a workforce of 2 employees on its EPFO records as of Apr 05, 2024, across 1 active EPFO establishment.
GST
Medicaps has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AABCM1905G1Z1 | Madhya Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Medicaps Limited, buy the company report.
Recent activity
Medicaps Limited has 30 board changes on record since 1983: 18 appointments and 12 cessations. The latest: Pramod Fatehpuria ceased to be Director on 28 May 2024.
31 earlier events are in the company report.
Frequently asked questions
Medicaps is an active public limited company based in Indore, Madhya Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 06 August 1983 (43+ years old) and is registered under CIN L70100MP1983PLC002231. Listed on BSE: 523144 and NSE: MEDICAPQ.
Medicaps reported revenue of ₹12.45 Cr for FY 2025-26 (down 51.1% YoY) based on consolidated financials.
Medicaps has 6 current directors:
- Alok K Garg - Managing Director
- Ramesh Chandra Mittal - Director
- Ashok Agrawal Omprakash - Director
- Kusum Mittal - Director
- Dharmendra Solanki - Director
- Gajendra Singh - Director
The latest financial statements of Medicaps on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 18 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Medicaps is 23AABCM1905G1Z1, registered in Madhya Pradesh.
The CIN (Corporate Identification Number) of Medicaps is L70100MP1983PLC002231. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Medicaps is a listed company as per MCA records. Its shares are listed on both BSE (code: 523144) and NSE (symbol: MEDICAPQ).
Medicaps has 22 court cases on record: 16 filed by the company and 6 filed against it. 10 are pending. Most are in the district courts.
Medicaps was incorporated on 06 August 1983, making it 43+ years old. It is registered with the Registrar of Companies, Gwalior.
Medicaps has 23 deals on record (23 market trades); the latest was in January 2025.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
